An interventional study of Gastric Bypass Stent System in Fibrosis and Liver, sponsored by MDCECRO LLC. Recruiting at 2 sites in Latvia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-08.
Sponsored by MDCECRO LLC · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity and holds potential as a non-invasive technique for managing hepatic fibrosis. This pilot, prospective, single-arm, clinical investigation aims to evaluate the safety and performance of the Gastric Bypass Stent System for hepatic fibrosis treatment in Europe. This clinical investigation and the ongoing clinical investigation (Protocol number: BL-RD08-040) will be used to evaluate the safety and performance of the investigational device for the intended use.
1,272 studies on the registry are indexed under Fibrosis; 278 are open to participants now.
This study's planned enrollment of 10 is below the median of 64 across 842 interventional studies indexed under Fibrosis.
Browse Fibrosis studies →MDCECRO LLC is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subjects who meet all of the following criteria are eligible for this clinical investigation:
Medical history suggests suspected or confirmed NASH fibrosis. Meeting any of the following criteria indicates NASH liver fibrosis:
Liver biopsy confirming NASH within 6 months before the randomization date, with liver biopsy fibrosis stage 1-3, NAS ≥3, and at least a score of 1 for the following NAS components:
Subjects who meet any of the following criteria are not eligible for this clinical investigation:
Note: Anti-HCV positive, but HCV-RNA negative HCV patients can be included, based on investigator's judgement, if it's not the primary reason for the fibrosis. Anti-HBc positive, but HBs-Ag negative patients can be included, based on investigator's judgement.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In total, 10 subjects will be enrolled from 2 investigational sites located in Latvia. Any subject participating in this clinical investigation will not be replaced once withdrawn or lost to follow-up. This study includes 3 phases; screening period, procedural period, and a follow-up period. Following screening, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 3; Day 0).
Device: Gastric Bypass Stent System
The Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity holds potential as a non-invasive technique for managing hepatic fibrosis. This clinical investigation will be used to evaluate the safety and performance of the investigational device for the intended use.
Change from baseline in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN score) at 6 months after procedure (i.e. device implantation)
* Percentage of NAFLD activity score (NAS) reduction without worsening of fibrosis stage; * Percentage of improvement in fibrosis stage and no deterioration in NAFLD activity score (NAS)
Time frame: 6 months
Relative percentage change in Total Weight Loss (TWL%) and changes in BMI
Relative percentage change in Total Weight Loss (TWL%) and changes in BMI at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.
Time frame: 12 months
Changes in Fibroscan Controlled Attenuation Parameter (CAP) and Liver Stiffness Measurement (LSM)
Changes in Fibroscan Controlled Attenuation Parameter (CAP) and Liver Stiffness Measurement (LSM) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.
Time frame: 12 months
Changes in liver inflammation/injury-related markers (ALT, AST, GGT, ALP, Total Bilirubin, Direct Bilirubin)
Changes in liver inflammation/injury-related markers (ALT, AST, GGT, ALP, Total Bilirubin, Direct Bilirubin) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.
Time frame: 12 months
Changes in blood glucose-related markers (fasting insulin, fasting glucose, fasting C-peptide)
Changes in blood glucose-related markers (fasting insulin, fasting glucose, fasting C-peptide, insulin resistance (HOMA-IR)) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.
Time frame: 12 months
Changes in blood lipid-related markers (total cholesterol [TC], triglyceride [TG], high-density lipoprotein C [HDL-C], low-density lipoprotein C [LDL-C]), apolipoprotein A1, apolipoprotein B, apolipoprotein CIII, lipoprotein(a))
Changes in blood lipid-related markers (total cholesterol \[TC\], triglyceride \[TG\], high-density lipoprotein C \[HDL-C\], low-density lipoprotein C \[LDL-C\]), apolipoprotein A1, apolipoprotein B, apolipoprotein CIII, lipoprotein(a)) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.
Time frame: 12 months
Changes in blood glucose-related markers (insulin resistance (HOMA-IR))
Changes in blood glucose-related markers (insulin resistance (HOMA-IR)) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.
Time frame: 12 months
Changes in liver fibrosis-related markers (Forns Index)
Changes in liver fibrosis-related markers (Forns Index) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.
Time frame: 12 months
Changes in liver fibrosis-related markers (Fibrosis-4 Index (FIB-4))
Changes in liver fibrosis-related markers (Fibrosis-4 Index (FIB-4)) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.
Time frame: 12 months
Changes in liver fibrosis-related markers (S Index)
Changes in liver fibrosis-related markers (S Index) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.
Time frame: 12 months
Changes in liver fibrosis-related markers (AST to Platelet Ratio Index (APRI))
Changes in liver fibrosis-related markers (AST to Platelet Ratio Index (APRI)) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Dec 2025, 18 months after the start.
Of 186 non-industry interventional studies with no phase under Fibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 18 months is below that.
Counting every sponsor, half of 195 studies reached it within 32 months; a quarter within 18 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MDCECRO LLC